Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) EPS (Weighted Average and Diluted) (2021 - 2023)

Candel Therapeutics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.39 for Q4 2023.

  • For Q4 2023, EPS (Weighted Average and Diluted) fell 116.67% year-over-year to -$0.39; the TTM value through Dec 2023 reached -$1.31, down 101.54%, while the annual FY2024 figure was -$1.74, 32.82% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2023 was -$0.39 at Candel Therapeutics, down from -$0.29 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.51 in Q4 2021 and bottomed at -$0.57 in Q3 2021.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.3 (2022), against an average of -$0.22.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 69.14% in 2022 before it plummeted 900.0% in 2023.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.51 in 2021, then tumbled by 135.29% to -$0.18 in 2022, then plummeted by 116.67% to -$0.39 in 2023.
  • Per Business Quant, the three most recent readings for CADL's EPS (Weighted Average and Diluted) are -$0.39 (Q4 2023), -$0.29 (Q3 2023), and -$0.33 (Q2 2023).